Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 999-1009

  Danielli, Riccardo ^a   Patuzzo, Roberto ^b   Di Giacomo, Anna Maria ^a   Gallino, Gianfranco ^b   Maurichi, Andrea ^b   Di Florio, Annabella ^b   Cutaia, Ornella ^a   Lazzeri, Andrea ^a   Fazio, Carolina ^a   Miracco, Clelia ^c   Giovannoni, Leonardo ^d   Elia, Giuliano ^e   Neri, Dario ^f   Maio, Michele ^a   Santinami, Mario ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Philogen SpA   (Italy)

^e PHILOCHEM AG   (Switzerland)

^f ETH ZURICH   (Switzerland)

Author keywords

Bystander effect; Immunocytokines; Intralesional delivery; Melanoma; Neoadjuvant

Indexed keywords

DARLEUKIN; DIPYRONE; FIBROMUN; LOCAL ANESTHETIC AGENT; PARACETAMOL; HYBRID PROTEIN; L19-IL2 IMMUNOCYTOKINE; L19MTNFALPHA PROTEIN;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER PATIENT; CANCER STAGING; CHILL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE NECROSIS; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE ULCER; MALE; METASTATIC MELANOMA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT RESPONSE; VERTIGO; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG POTENTIATION; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; SKIN NEOPLASMS; YOUNG ADULT;

ADULT; AGED; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84937968502     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1704-6     Document Type: Article

References (34)

1. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, Verhoef C, Verrecchia F, Soteldo J (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104(4):391–396. doi:10.1002/jso.22029
2. Si Z, Hersey P, Coates AS (1996) Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6(3):247–255
3. von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61(6):1071–1074
4. Kubo H, Ashida A, Matsumoto K, Kageshita T, Yamamoto A, Saida T (2008) Interferon-beta therapy for malignant melanoma: The dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 300(6):297–301. doi:10.1007/s00403-008-0841-6
5. Gutwald JG, Groth W, Mahrle G (1994) Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma. Br J Dermatol 130(4):541–542
6. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620–1626. doi:10.1038/sj.bjc.6601320
7. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pfohler C, Pawelec G, Garbe C (2010) High response rate after intratumoral treatment with interleukin-2: Results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116(17):4139–4146. doi:10.1002/cncr.25156
8. Boyd KU, Wehrli BM, Temple CL (2011) Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 104(7):711–717. doi:10.1002/jso.21968
9. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, Carretero G (2009) Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. Actas Dermosifiliogr 100(7):571–585
10. Weide B, Eigentler TK, Pflugfelder A et al (2011) Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 60(4):487–493. doi:10.1007/s00262-010-0957-3
11. Weide B, Eigentler TK, Pflugfelder A et al (2014) Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res 2(7):668–678. doi:10.1158/2326-6066.CIR-13-0206
12. Pasche N, Neri D (2012) Immunocytokines: A novel class of potent armed antibodies. Drug Discov Today 17(11–12):583–590. doi:10.1016/j.drudis.2012.01.007
13. Carnemolla B, Borsi L, Balza E et al (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5):1659–1665. doi:10.1182/blood.V99.5.1659
14. Pretto F, Elia G, Castioni N, Neri D (2014) Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother 63(9):901–910. doi:10.1007/s00262-014-1562-7
15. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133(3):751–758. doi:10.1038/jid.2012.376
16. Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M (2011) Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2(10):739–751
17. Eigentler TK, Weide B, de Braud F et al (2011) A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 17(24):7732–7742. doi:10.1158/1078-0432.CCR-11-1203
18. Papadia F, Basso V, Patuzzo R et al (2013) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 107(2):173–179. doi:10.1002/jso.23168
19. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA (2013) Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 19(5):997–1008. doi:10.1158/1078-0432.CCR-12-2214
20. Temple-Oberle CF, Byers BA, Hurdle V, Fyfe A, McKinnon JG (2014) Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol 109(4):327–331. doi:10.1002/jso.23556
21. Hassan S, Petrella T, Zhang T et al (2014) Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease. Ann Surg Oncol. doi:10.1245/s10434-014-4199-z
22. Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18(6):405–411. doi:10.1097/CMR.0b013e32831328c7
23. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17(3):718–730. doi:10.1245/s10434-009-0809-6
24. Lotze MT (1995) Biologic therapy with interleukin-2: Preclinical studies. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, pp 207–233
25. van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11(4):397–408. doi:10.1634/theoncologist.11-4-397
26. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6):2409–2414. doi:10.1182/blood-2005-06-2399
27. Berntsen A, Brimnes MK, thor Straten P, Svane IM (2010) Increase of circulating CD4+ CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 33(4):425–434. doi:10.1097/CJI.0b013e3181cd870f
28. Martens A, Zelba H, Garbe C, Pawelec G, Weide B (2014) Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses? Oncoimmunology 3(1):e27845. doi:10.4161/onci.27845
29. Weide B, Martens A, Zelba H et al (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20(6):1601–1609. doi:10.1158/1078-0432.CCR-13-2508
30. Fadaki N, Cardona-Huerta S, Martineau L et al (2012) Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep 2012. doi:10.1136/bcr-2012-007034
31. Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA (2013) Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol 31(16):e251–e253. doi:10.1200/JCO.2012.45.3845
32. Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP (2013) Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 31(3):e40–e43. doi:10.1200/JCO.2012.43.7061
33. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
34. Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15(23):7412–7420. doi:10.1158/1078-0432.CCR-09-1624